Apimeds Pharmaceuticals US (APUS) Change in Accured Expenses (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Change in Accured Expenses came in at $448494.0 in Q3 2025, up 296.45% on a YoY basis from $113128.0 in Q3 2024, and up 154.96% quarter-over-quarter from -$816064.0 in Q2 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Change in Accured Expenses (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Change in Accured Expenses for 2 consecutive years, with $448494.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Change in Accured Expenses rose 296.45% year-over-year to $448494.0; the trailing twelve-month figure through Sep 2025 stood at $151675.0 (changed N/A YoY), and the FY2024 full-year result was $536752.0, up 904.48% from the prior year.
- Change in Accured Expenses improved to $448494.0 in Q3 2025 per APUS's latest filing, from -$816064.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $448494.0 in Q3 2025 and bottomed at -$816064.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -13.91 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 448,494.00 |
| Jun 30, 2025 | -816,064.00 |
| Mar 31, 2025 | 344,012.00 |
| Dec 31, 2024 | 175,233.00 |
| Sep 30, 2024 | 113,128.00 |
| Jun 30, 2024 | 243,184.00 |
| Mar 31, 2024 | 5,207.00 |